8-K current report · filed Oct 27, 2026

Altimmune, Inc. (ALT) 8-K Current Report: October 27, 2026

Item 5.02Item 7.01Item EX-99.1ALT overview

Short answer

Altimmune, Inc. (ALT) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026.

Altimmune, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Board expands from nine to eleven directors, adding Peter Greenleaf and Alex Howarth effective November 2, 2026
  • Greenleaf brings former CEO and biopharmaceutical commercial leadership experience, strengthening strategic and industry oversight
  • Howarth adds former CFO and operating expertise, relevant to capital allocation, financing and corporate execution
  • Each receives options for 160,000 shares plus a $40,000 annual cash retainer, creating shareholder dilution and compensation costs
  • Gill, Sayare and Schafer will retire after the 2027 annual meeting, with no stated disagreement, creating planned board turnover

Item 7.01 · Regulation FD Disclosure

  • Press release announces new Board appointments, signaling a change in governance and potential strategic oversight
  • Exhibit 99.1 contains appointment details, including director identities and effective terms

Item EX-99.1 · Exhibit EX-99.1

  • Peter Greenleaf and Alex Howarth join the board November 2, 2026, adding late-stage development, commercialization, licensing and M&A expertise
  • Three current directors retire at the 2027 annual meeting, marking planned board succession during Altimmune’s transition toward commercialization
  • Board changes support pemvidutide’s Phase 3 MASH development and potential expansion across AUD and ALD indications
  • Pemvidutide’s PERFORMA Phase 3 MASH trial began July 2026, while RESTORE enrollment completed in August 2026
  • Howarth’s Madrigal experience and Greenleaf’s prior $1.2 billion Sucampo transaction strengthen strategic options, including partnering or M&A execution

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Altimmune, Inc. 8-K filings

Get the next ALT 8-K as it lands

Follow ALT for push alerts, or ask the research agent what this filing means.